fast impact of lifestyle and functional interventions on adults affected by non-alcoholic liver...
TRANSCRIPT
INTRODUCTION and PURPOSE
MATERIALS and METHODS
Fast impact of lifestyle and functional interventions on adults
affected by non-alcoholic fatty liver disease NAFLD
L. Maselli12
, M. Salamone2, A. Saggioro
3, G.M. Nardi
12
1 "Sapienza" University, Department of Oral and Maxillofacial Sciences, Rome, Italy. Electronic address: [email protected]
2 Italian Lifestyle Medicine Association – ILMA – National Department of Lifestyle Sciences, Bari, Italy.
3 Centro di Medicina, Sede di Mestre, Mestre, Italy-Gastroenterology.
In terms of public health, it’s important to early detect fatty liver disease, NAFLD and
metabolic syndrome, before they become chronic and develop metabolic
complications.
The aim of the study was to asses the effects of a nutraceutical approach combined
with Lifestyle Intervention (LSI) on patients with Non Alcoholic Fatty Liver Disease
and mild hypertransaminasemia.
In a 3-month study, 76 subjects, 50% male and 50% female with BMI between 18.3 and
31.0, received Metaclear® (1tab twice a day, before breakfast and before dinner), an
antioxidant, anti-inflammatory and lipophilic action formula, in conjunction with a
structured LSI program geared toward weight loss.
RESULTS and DISCUSSION
Insulin resistance, predisposing to lipolysis of peripheral fat with mobilization to and
uptake of fatty acids by the liver, is the most consistent underlying pathogenic factor of
Non Alcoholic Fatty Liver Disease (NAFLD) which is defined as accumulation of fat in the
liver in the presence of less than 20g of alcohol ingestion per day.
A growing body of evidence indicates that oxidative stress, free radicals, metabolic
deregulation caused by bio-metal toxicity and abnormal inflammatory reactions
contribute to the key event in Non Alcoholic Fatty Liver Disease.
We administered a questionnaire to patients, which consisted of 32 questions
concerning anthropometric data, lifestyle habits as diet, physical activity, level of
stress, diagnosed illness and diseases. Patients were subjected to blood test of AST,
ALT, ɣGT-total and direct bilirubin, and fasting serum glucose, as well as a lipid panel.
Figure 1 : Significant (p< 0.001) improvement of aminotransferases Figure 3: Significant (p< 0.001) improvement of quality of life
In this study blood tests showed at 90 days:
31,1% reduction of AST and a 32.2% reduction of ALT with statistical significance
(p<0.001) in comparison to time 0.
→ Average value of AST was reduced from 72,0 (st.dev. 41.1) to 49,6 (st.dev. 21,5).
→ Average value of ALT was reduced from 70,0 (st.dev. 41.1) to 47,4 (st.dev. 21.6).
ỿGT showed a 32.9% reduction (p<0.001) going from a value of 66.1 (st.dev. 30.2) to a
value of 44,3 (st.dev. 28.0).
Quality of Life indicators showed +17,2% improvement (p<0.001) during the period,
going from average 6,64 (st.dev. 1.32) to 7,79 (st.dev. 0.89).
All patients completed the study and 92% of the patients reported benefits
Metaclear® has been well tolerated by most of the patients. No severe side effects
were reported and only 2,6% of minor side effects (insomnia).
CONCLUSION
Lifestyle changes and treatment with Metaclear® both seems to effectively reduce the level of hepatic markers like AST, ALT and ỿGT and improve perceived quality of life in patients
affected by NAFLD and hypertransaminasemia. When used over 3 months as an adjunct to LSI, Metaclear® treatment, twice a day, helped subjects with NAFLD to achieve better
weight loss and enhanced long-term maintenance of weight loss with good tolerability profile.
Figure 2 : Significant (p< 0.001) improvement of ỿGT